Opinion|Videos|December 20, 2024
Data and Treatment Considerations for BCMA-Directed Bispecifics in RRMM
Author(s)Binod Dhakal, MD, MS
Panelist discusses how pivotal studies led to the approval of teclistamab in patients with less refractory multiple myeloma; the overall response rate was 63% and the progression of survival rate was 11.3 months.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please discuss other bispecific antibodies in the RRMM space.
Advertisement
Related to this article
During a live event, Sikander Ailawadhi, MD, and participants considered a case patient with relapsed multiple myeloma after a quadruplet induction who declined CAR T-cell therapy.
The UK's OPTIMUM trial showed significant differences with a more aggressive treatment regimen for high-risk newly diagnosed multiple myeloma, based on long-term follow-up.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Imlunestrant Plus Abemaciclib in ESR1-Mutated Breast Cancer
2
Daraxonrasib Combo Receives FDA Breakthrough Status in First-Line PDAC
3
Mosunetuzumab Combo Improves PFS in R/R Follicular Lymphoma
4
FDA Launches Expedited IND Pilot to Speed First-in-Human Trials
5